New targeted drug shows promise against Tough-to-Treat cancers
NCT ID NCT05009329
Summary
This study is testing an experimental drug called JAB-21822 (glecirasib) for people with advanced cancers that have a specific genetic change called KRAS G12C mutation. The trial aims to find the safest and most effective dose while checking if the drug can shrink tumors. It includes 315 adults with lung cancer or other solid tumors who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.